Advertisement
X

Childhood Cancer Survivors Too Need HPV Vaccine Focus

A Noida hospital is piloting HPV vaccination for childhood cancer survivors, highlighting the need to prevent HPV-related second cancers through long-term survivorship care.

As India expands its HPV vaccination programme to prevent cervical cancer, a new initiative at Uttar Pradesh’s government children hospital in Noida is turning attention to a group that could need special consideration: children who have survived cancer.

The Post Graduate Institute of Child Health (PGICH) has initiated a pilot project involving around 200 childhood cancer survivors aged 9–15 years to examine how HPV vaccination can be incorporated into their long-term follow-up care.

The initiative comes amid growing evidence that survivors of childhood cancer may face an increased risk of developing HPV-associated cancers decades after their original diagnosis.

The concern is not merely theoretical. A population-based study published in Cancer Epidemiology in 2024, which analysed 35,397 five-year survivors of childhood cancer through the US Surveillance, Epidemiology, and End Results (SEER) database, identified 42 subsequent HPV-associated malignancies, including cervical, vulvar, vaginal, anal, penile and oropharyngeal cancers.

The cancers developed a median of 25 years after the original cancer diagnosis. Although the 40-year cumulative incidence was 0.51%, the survivors had approximately 10 times the risk of HPV-associated malignancies compared with the general population, as per the study.

The findings underline why cancer survivorship needs to extend beyond monitoring for recurrence of the original disease. For some survivors, the risk of developing a second cancer can persist well into adulthood.

Cervical and oropharyngeal cancers were among the most frequently reported malignancies in the study. Treatment-related immunosuppression, impaired immune surveillance, radiotherapy and prolonged immunosuppressive therapy following haematopoietic stem cell transplantation (HSCT) may contribute to this increased vulnerability.

Dr Nita Radhakrishnan, Head of the Department of Paediatric Haematology-Oncology, PGICH, told The Health Outlook that HPV vaccination is particularly important for childhood cancer survivors, who may face additional long-term health risks.

“Preventing HPV-associated cancers is an important part of survivorship care and reducing the risk of second primary cancers,” said Dr Radhakrishnan, who is spearheading the project.

The need for such an intervention is reinforced by another study published in April 2026 in the Journal of Cancer Survivorship. Analysing data from 2,907 childhood, adolescent and young adult cancer survivors in the US, researchers found that only 27.31% had received at least one dose of the HPV vaccine. The finding points to a substantial gap in preventive care even in settings where childhood cancer survivorship services are established.

Advertisement

JD Rawat, Paediatric Surgeon and Director, PGICH, Noida, said, “The challenge is to ensure that children who survive cancer do not fall through the gaps in routine healthcare once their active treatment ends. Regular follow-up should address immunisation, nutrition, education, physical health and the risk of second cancers.”

The PGICH, Noida initiative assumes significance against the backdrop of India's nationwide HPV vaccination campaign, launched on February 28, 2026, targeting approximately 1.2 crore girls aged 14 years.

The voluntary, free-of-cost programme offers a single dose of the HPV vaccine at designated government health facilities, with parental consent. According to the Union Health Ministry, more than 80 lakh doses had been administered by September 11.

While the campaign marks an important step in cervical cancer prevention, its coverage figures do not indicate how many childhood cancer survivors have received the vaccine. Nor do they establish whether older adolescents, young adults and boys who have completed cancer treatment are being adequately counselled about HPV vaccination.

Advertisement

The government programme's current target is 14-year-old girls, whereas the PGICH pilot involves survivors aged 9–15 years. The initiative could help assess their awareness, vaccination needs and access to protection, and identify how HPV vaccination can become part of routine survivorship follow-up.

Dr Naveen Thacker, Executive Director of the International Paediatric Association and Director of Deep Children Hospital & Research Centre, Gandhidham-Kutch, Gujarat, batted for vaccination to be made an integral part of follow-up care for childhood cancer survivors, who could otherwise face an increased risk of HPV-related cancers.

A lifelong immunisation advocate and global paediatrics leader who was a key player in India's eradication of polio in 2014 told The Health Outlook that previous chemotherapy, radiation and prolonged immunosuppression could affect the body's ability to clear persistent HPV infections.

“International survivorship guidance recommends a three-dose HPV vaccine schedule for childhood cancer survivors, beginning at least six months after completion of cancer-directed treatment. The treating oncologist should determine the appropriate timing based on the patient's treatment history and immune status.”

Advertisement

The guidelines were launched by the International Paediatric Association (IPA) on World Cancer Day, February 4, 2026, in partnership with the American Cancer Society.

The Indian Academy of Paediatrics (IAP) also recommends HPV vaccination for both girls and boys, making it important to address the needs of male survivors as well as those who may fall outside the government's age-specific vaccination campaign.

“Childhood cancer survivorship must become a public health priority. We need to look beyond cure and address the long-term physical, psychological and social needs of survivors, integrating comprehensive survivorship care into our public health programmes,” said Prof. (Dr.) Ravi Mehrotra, a physician-scientist, cancer epidemiologist, and founder of the Centre for Health Innovation and Policy (CHIP) Foundation.

Prof. (Dr) Jyotsna Madan, a Pathologist and former director of the PGICH, Noida, added, “Cervical cancer is one of the few cancers that can be prevented through vaccination and appropriate screening. HPV vaccination offers a tremendous opportunity to reduce the future burden of this disease.”

Advertisement

India's cervical cancer burden makes the case for strengthening prevention even more urgent. The country recorded an estimated 1.27 lakh new cases and nearly 79,906 deaths in 2022, according to GLOBOCAN estimates, placing it among the countries with the highest incidence and mortality.

With childhood cancer survival improving, PGICH is also examining other aspects of survivorship, including school reintegration and the psychosocial challenges faced by children returning to normal life after treatment.

HPV vaccines protect against high-risk types 16 and 18, which account for a substantial proportion of cervical cancers. Depending on the vaccine formulation, they can also protect against types 6 and 11, which cause genital warts.

The World Health Organisation's global cervical cancer elimination strategy sets a 90-70-90 target for 2030: 90% of girls fully vaccinated against HPV by the age of 15, 70% of women screened using a high-performance test by the ages of 35 and 45, and 90% of women identified with cervical disease receiving appropriate treatment. The WHO estimates that achieving these targets could avert 74 million new cases and 62 million deaths by 2120.

According to the global health agency, cervical cancer is largely preventable through a comprehensive, life-course approach combining public awareness, health education, HPV vaccination, screening and timely treatment. Vaccinating girls aged 9–14 years before exposure to the virus is highly effective in preventing HPV infection and subsequent cervical cancer and other HPV-related malignancies.

For childhood cancer survivors, emphasised the doctors, the challenge is to ensure that protection against a second cancer becomes part of the journey back to a healthy life, rather than an afterthought once cancer treatment is over.

Published At:
US